Current Study
COPD | AER-01-002
A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER-01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease
Study Status
Closed
Duration
Up to 10 weeks
Clinic Visits
Up to 7
Phone Check-ins
1
Study Overview
Location
Spearwood & Osborne Park
Phase
Phase 2a
Study Duration
Up to 10 weeks
Main Entry Criteria
- 40 to 80 years of age
- Confirmed diagnosis of COPD
- Participant has had less than 2 COPD exacerbations requiring hospitalization in the past year
There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.
Main Exclusion Criteria
Assessments
- ECG
- Blood pressure and pulse
- Spirometry
- Blood and urine tests
- Questionnaires
At a Glance
Clinic Visits
Up to 7
Phone Calls
1
Duration
Up to 10 weeks